Abstract: Objective The aim of this study was to summarize the clinical feature of patients with anti-tuberculosis drug-induced liver injury (DILI). Methods 142 patients with anti-tuberculosis DILI were enrolled in this study between January 2012 and March 2020, and the clinical catalogue and liver injury severity were clarified. Results There were hepatocyte injury in 109, cholestasis in 17 and mixed injury in 16 in our series; serum ALT levels in patients with hepatocyte injury, cholestasis and mixed injury were (652.5±350.6)U/L, (172.6±92.8)U/L and (380.6±218.5)U/L, significantly different among them (P<0.05), serum AST levels were (451.8±418.1)U/L, (185.5±105.2)U/L and (276.0±144.5)U/L, significantly different among them (P<0.05), serum ALP levels were (94.5±77.5)U/L, (468.8±312.8)U/L and 209.1±144.5)U/L(P<0.05), total serum bilirubin levels were (42.3±32.3)μmol/L, (126.8±103.5)μmol/L and (57.8±42.8)μmol/L(P<0.05) and serum albumin levels were (36.8±7.2)g/L, (32.2±6.8)g/L and (33.0±7.0)g/L, all significantly different among them (P<0.05); there were mild liver injury in 102, moderate liver injury in 14 and severe liver injury in 26 patients out of the 142 patients, and the clinical feature of patients with mild liver injury included more younger than 60 year old, no underlying liver disease and presented with hepatocy injury; 95 patients recovered and 47 not, and the recovered patients had more younger patients, low serum AST, ALP and bilirubin levels with relatively higher serum albumin levels, significantly different compared to those unrecovered (P<0.05). Conclusion The majority of patients with anti-tuberculosis DILI presents with hepatocyte injury, and those with low serum albumin and high total serum bilirubin levels are prone to have a poor prognosis.

Key words: Drug-induced liver injury, Anti-tuberculosis agents, Clinical catalogue, Liver injury severity, Prognosis